Physician profile
Robert K Roby
NPI 1508809971
$2,639.44
in general payments reported to CMS, 2019-2025
29 companies · $791 in 2025
The $791 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $215 · 2021: $13.11 · 2023: $106 · 2024: $699 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.86 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $389.03 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $339.97 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $245.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $172.16 | 2019-2025 | |
| Pfizer INC. | $164.67 | 2019-2025 | |
| Lilly USA, LLC | $154.09 | 2024-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $117.01 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $110.27 | 2019-2020 | |
| Sanofi Pasteur INC. | $108.29 | 2019-2025 | |
| Astellas Pharma US INC | $97.99 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $97.89 | 2019-2024 | |
| Gilead Sciences, INC. | $90.86 | 2019-2025 | |
| Amgen INC. | $81.86 | 2019-2020 | |
| Abbvie INC. | $59.74 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $52.64 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $45.44 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $45.12 | 2024 | |
| Biogen, INC. | $41.43 | 2024 | Skyclarys |
| Sumitomo Pharma America, INC. | $40.49 | 2023-2024 | Gemtesa |
| Eisai INC. | $33.74 | 2025 | |
| Janssen Pharmaceuticals, INC | $24.50 | 2019 | |
| Dexcom, INC. | $21.02 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.75 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $19.15 | 2025 | Strensiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.58 | 2019 | |
| Axsome Therapeutics, INC. | $14.17 | 2025 | Symbravo |
| Acadia Pharmaceuticals INC | $13.76 | 2020 | |
| Orexo US, INC. | $12.27 | 2020 | |
| Hikma Pharmaceuticals USA | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Roby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.